Last reviewed · How we verify
Secukinumab 300 MG; Tofacitinib 11mg
Secukinumab 300 MG; Tofacitinib 11mg is a Small molecule drug developed by Second Affiliated Hospital, School of Medicine, Zhejiang University. It is currently in Phase 1 development.
At a glance
| Generic name | Secukinumab 300 MG; Tofacitinib 11mg |
|---|---|
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Secukinumab 300 MG; Tofacitinib 11mg CI brief — competitive landscape report
- Secukinumab 300 MG; Tofacitinib 11mg updates RSS · CI watch RSS
- Second Affiliated Hospital, School of Medicine, Zhejiang University portfolio CI
Frequently asked questions about Secukinumab 300 MG; Tofacitinib 11mg
What is Secukinumab 300 MG; Tofacitinib 11mg?
Secukinumab 300 MG; Tofacitinib 11mg is a Small molecule drug developed by Second Affiliated Hospital, School of Medicine, Zhejiang University.
Who makes Secukinumab 300 MG; Tofacitinib 11mg?
Secukinumab 300 MG; Tofacitinib 11mg is developed by Second Affiliated Hospital, School of Medicine, Zhejiang University (see full Second Affiliated Hospital, School of Medicine, Zhejiang University pipeline at /company/second-affiliated-hospital-school-of-medicine-zhejiang-university).
What development phase is Secukinumab 300 MG; Tofacitinib 11mg in?
Secukinumab 300 MG; Tofacitinib 11mg is in Phase 1.